Microbiotix Finalizes Krw 20 Billion Series B, Securing Korea's First Bacteriophage Clinical Trial
MICROBIOTIX FINALIZES KRW 20 BILLION SERIES B, SECURING KOREA'S FIRST BACTERIOPHAGE CLINICAL TRIAL
MICROBIOTIX: CUMULATIVE INVESTMENT AMOUNT ACROSS ROUNDS HAS NOW REACHED 29 BILLION KRW
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Intel Better-Than-Expected Earnings Released, Stock Surges 20% After-Hours, AI Computing Power Enters CPU Moment?

Semiconductor Sector Continues to Rise, Should Retail Investors Buy Intel or AMD?
Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Tradingkey







